Analyze Diet

Topic:Vaccine development

Vaccine development in horses involves the creation and refinement of immunizations to protect equine populations from infectious diseases. This process includes identifying antigens, formulating vaccines, and evaluating their safety and efficacy through clinical trials. Vaccines stimulate the horse's immune system to recognize and combat specific pathogens, thereby reducing the incidence and severity of diseases. Common equine vaccines target diseases such as equine influenza, tetanus, and West Nile virus. This page compiles peer-reviewed research studies and scholarly articles that explore the methodologies, challenges, and advancements in vaccine development for equine health.
Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process.
Journal of virology    May 1, 1997   Volume 71, Issue 5 3840-3852 doi: 10.1128/JVI.71.5.3840-3852.1997
Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC.Equine infectious anemia virus (EIAV) provides a natural model system by which immunological control of lentivirus infections may be studied. To date, no detailed study addressing in parallel both the humoral and cellular immune responses induced in horses upon infection by EIAV has been conducted. Therefore, we initiated the first comprehensive characterization of the cellular and humoral immune responses during clinical progression from chronic disease to inapparent stages of EIAV infection. Using new analyses of antibody avidity and antibody epitope conformation dependence that had not been...
Transforming growth factor-beta induced by live or ultraviolet-inactivated equid herpes virus type-1 mediates immunosuppression in the horse.
Immunology    April 1, 1997   Volume 90, Issue 4 586-591 doi: 10.1046/j.1365-2567.1997.00202.x
Charan S, Palmer K, Chester P, Mire-Sluis AR, Meager A, Edington N.Up to 21 days after exposure to live or ultraviolet-inactivated equid herpesvirus type-1 (EHV-1) autologous serum from ponies caused an immunosuppressive effect if incorporated into T-cell proliferation assays to EHV-1. The suppressive factor in the sera of ponies also inhibited T-cell response to phytohaemagglutinin. Increased levels of circulating activated transforming growth factor-beta 1 (TGF-beta 1) were detected, and the suppressive activity of the serum could be reversed by antibody to TGF-beta 1. In a challenge experiment the ponies which exhibited circulating TGF-beta 1 activity succ...
Simulation studies of vaccination strategies in African horse sickness.
Vaccine    April 1, 1997   Volume 15, Issue 5 519-524 doi: 10.1016/s0264-410x(97)00220-x
Lord CC, Woolhouse ME, Mellor PS.A simulation model including two hosts (horses and donkeys) and one vector (Culicoides imicola) for African horse sickness in Spain is extended to consider vaccination strategies. If hosts were protected prior to virus introduction, elimination of simulated epidemics was related nonlinearly to the fraction protected. Protecting donkeys as well as horses increased the effectiveness of vaccination. Prevention of 50% of epidemics required 75% coverage of horses and donkeys or 90% coverage of horses only. Protection after the introduction of the virus was rarely successful in preventing outbreaks....
Use of Rhodococcus equi virulence-associated protein for immunization of foals against R equi pneumonia.
American journal of veterinary research    April 1, 1997   Volume 58, Issue 4 356-359 
Prescott JF, Nicholson VM, Patterson MC, Zandona Meleiro MC, Caterino de Araujo A, Yager JA, Holmes MA.To evaluate use of the virulence-associated protein of Rhodococcus equi in immunizing foals against R equi pneumonia. Methods: Eight (experimental group) and 6 (controls) mares with their foals. Methods: Virulence-associated protein extracted from R equi was used to prepare an acetone-precipitated. Triton X-extracted (APTX) antigen. After determination of the efficacy of passive immunization, in untreated foals or in foals given plasma from a horse vaccinated with APTX antigen or from a nonvaccinated horse, a field trial was done to evaluate the efficacy of vaccination of 8 mares, twice with A...
Case studies in wildlife immunocontraception: wild and feral equids and white-tailed deer.
Reproduction, fertility, and development    January 1, 1997   Volume 9, Issue 1 105-110 doi: 10.1071/r96052
Kirkpatrick JF, Turner JW, Liu IK, Fayrer-Hosken R, Rutberg AT.Non-lethal management methods are required for wild equids that are protected by law and for deer inhabiting areas where lethal controls are not legal or safe. Single or multiple inoculations of porcine zona pellucida (PZP) vaccine have been delivered to wild horses and deer by means of darts. Contraceptive efficacy in horses after two inoculations ranged from 90% to 100%, and after a single inoculation ranged from 19% to 28%. Mares given a controlled-release form of the vaccine had foaling rates ranging from 7% to 20%. No detectable changes in social organization or behaviours among treated h...
Mutational changes in the hemagglutinin of equine H3 influenza viruses result in the introduction of a glycosylation site which enhances the infectivity of the viruses.
Folia microbiologica    January 1, 1997   Volume 42, Issue 4 390-394 doi: 10.1007/BF02816955
Adeyefa CA, McCauley JW, Tomori O.The complete amino acid sequences of the hemagglutinin (HA) glycoprotein of three equine-2 influenza viruses from tropical Africa are presented in comparison with that of a well characterized European equine-2 virus (Suffolk/89) and a consensus sequence from the database. The sequences of the tropical African viruses were deduced from the complete nucleotide sequences of their HA genes reported earlier. Mutational changes in the nucleotide sequences resulted in amino acid changes in the HA which led to the introduction of a new asparagine-linked (N-linked) glycosylation site in two viruses. Th...
Recombinant baculovirus-synthesized African horsesickness virus (AHSV) outer-capsid protein VP2 provides protection against virulent AHSV challenge.
The Journal of general virology    September 1, 1996   Volume 77 ( Pt 9) 2053-2057 doi: 10.1099/0022-1317-77-9-2053
Roy P, Bishop DH, Howard S, Aitchison H, Erasmus B.African horsesickness virus serotype 4 (AHSV-4) outer-capsid proteins VP2 or VP2 and VP5, prepared from single or dual recombinant baculovirus expression vectors grown in Sf9 insect cells, were administered in different amounts to horses and the neutralizing antibody responses were measured. Control and vaccinated horses were challenged with virulent AHSV-4 6 months later and monitored post challenge. The results indicated that two inoculations of extracts containing VP2 and VP5, or VP2 alone, in doses of 5 micrograms VP2 or more per horse, were sufficient to elicit protection against African ...
Suppression of testicular function using two dose rates of a reversible water soluble gonadotrophin releasing hormone (GnRH) vaccine in colts.
Australian veterinary journal    September 1, 1996   Volume 74, Issue 3 228-235 doi: 10.1111/j.1751-0813.1996.tb15410.x
Dowsett KF, Knott LM, Tshewang U, Jackson AE, Bodero DA, Trigg TE.To investigate the effect of two dose rates (200 and 400 ng) of a gonadotrophin releasing hormone (GnRH) vaccine on testicular function. Methods: A vaccination dose rate experiment. Methods: Two injections were administered 4 weeks apart to six colts in each treatment group. To maintain immunosuppression until the end of the breeding season, a third injection was given if antibody titres fell below 1000. Results: Effective antibody titres were present for 12 to 27 weeks. Testosterone concentrations decreased from 2.22 to 0.31 nmol/L 6 weeks after primary vaccination. Androstenedione concentrat...
Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis.
Annals of internal medicine    August 1, 1996   Volume 125, Issue 3 233-236 doi: 10.7326/0003-4819-125-3-199608010-00012
Wilde H, Thipkong P, Sitprija V, Chaiyabutr N.Active immunization against infectious disease is important. However, much of our world faces poverty, social injustice, and warfare, all of which cause universal immunization to remain a distant dream. Agents that provide passive immunity thus remain essential biologicals. The most important of these are human or equine antisera against rabies, tetanus, diphtheria, and snake antivenins. Homologous products are either unavailable or unaffordable in places where they are needed the most. Less expensive heterologous (equine) antisera can be purified and are safe to use, but these antisera are al...
Multiple gene expression in baculovirus system. Third generation vaccines for bluetongue disease and African horsesickness disease.
Annals of the New York Academy of Sciences    July 23, 1996   Volume 791 318-332 doi: 10.1111/j.1749-6632.1996.tb53539.x
Roy P.No abstract available
Equine herpesvirus type 2 (EHV-2) as a predisposing factor for Rhodococcus equi pneumonia in foals: prevention of the bifactorial disease with EHV-2 immunostimulating complexes.
Veterinary microbiology    July 1, 1996   Volume 51, Issue 1-2 55-68 doi: 10.1016/0378-1135(96)00032-6
Nordengrahn A, Rusvai M, Merza M, Ekström J, Morein B, Belák S.Equine herpesvirus type 2 (EHV-2), a member of the Gammaherpesvirinae subfamily, was studied in a two-phase respiratory disease complex of young foals as a predisposing factor for the secondary bacterial invasion of lungs with Rhodococcus equi (R. equi). Foals were immunized against EHV-2 on a farm where R. equi pneumonia regularly occurred during the last years. The immunizations were performed by using a subunit vaccine which selectively presents envelope glycoproteins of EHV-2 in a multimeric form of immunostimulating complexes (iscoms). The etiological role of EHV-2 was estimated by observ...
Full protection against African horsesickness (AHS) in horses induced by baculovirus-derived AHS virus serotype 4 VP2, VP5 and VP7.
The Journal of general virology    June 1, 1996   Volume 77 ( Pt 6) 1211-1221 doi: 10.1099/0022-1317-77-6-1211
Martínez-Torrecuadrada JL, Díaz-Laviada M, Roy P, Sánchez C, Vela C, Sánchez-Vizcaíno JM, Casal JI.African horsesickness virus serotype 4 (AHSV-4) outer capsid protein VP2, or VP2 and VP5 plus inner capsid protein VP7, derived from single or dual recombinant baculovirus expression vectors were used in different combinations to immunize horses. When the proteins were purified by affinity chromatography, the combination of all three proteins induced low levels of neutralizing antibodies and conferred protection against virulent virus challenge. However, purified VP2 or VP2 and VP5 in the absence of VP7 failed to induce neutralizing antibodies and protection. Immunization with non-purified pro...
Equine influenza.
Comparative immunology, microbiology and infectious diseases    June 1, 1996   Volume 19, Issue 3 205-211 doi: 10.1016/0147-9571(96)00006-9
Timoney PJ.A highly contagious virus infection of horses, influenza is the single most important equine respiratory disease in many countries. Two subtypes of equine influenza virus have been identified, A/equine-1 and A/equine-2, neither of which immunologically cross-reacts. In the case of A/equine-2 virus, two lineages exist, American and European, which appear to have evolved independently of one another. The acute febrile respiratory disease characteristic of influenza is frequently complicated by secondary bacterial infection, especially in unvaccinated horses. Primarily a respiratory-borne infecti...
Antigenic and genetic evolution of equine H3N8 influenza A viruses.
The Journal of general virology    April 1, 1996   Volume 77 ( Pt 4) 661-671 doi: 10.1099/0022-1317-77-4-661
Daly JM, Lai AC, Binns MM, Chambers TM, Barrandeguy M, Mumford JA.Evolution of equine influenza a H3N8 viruses was examined by antigenic and genetic analysis of a collection isolates from around the world. It was noted that antigenic and genetic variants of equine H3N8 viruses cocirculate, and in particular that variants currently circulating in Europe and the USA are distinguishable from one another both in terms of antigenic reactivity and genetic structure of the HA1 portion of the haemagglutinin (HA) molecule. Whilst the divergent evolution of American and European isolates may be due to geographical isolation of the two gene pools, some mixing is believ...
Characterization of protective and enhancing immune responses to equine infectious anemia virus resulting from experimental vaccines.
AIDS research and human retroviruses    March 20, 1996   Volume 12, Issue 5 413-415 doi: 10.1089/aid.1996.12.413
Montelaro RC, Grund C, Raabe M, Woodson B, Cook RF, Cook S, Issel CJ.No abstract available
Fine specificity of equine infectious anaemia virus gp90-specific antibodies associated with protective and enhancing immune responses in experimentally infected and immunized ponies.
The Journal of general virology    March 1, 1996   Volume 77 ( Pt 3) 435-442 doi: 10.1099/0022-1317-77-3-435
Grund CH, Lechman ER, Pezzuolo NA, Issel CJ, Montelaro RC.Equine infectious anaemia virus (EIAV) provides a model for examining the natural immunological control of a persistent lentivirus infection and for evaluating the efficacy of various vaccine strategies. As an initial characterization of antibody responses associated with protective or enhancing immune responses elicited by experimental infections or vaccinations, we have utilized synthetic peptide ELISA to characterize the fine specificity of antibodies to linear determinants of the EIAV surface glycoprotein, gp90. The data indicated that serum antibodies associated with protective or enhanci...
Lack of virulence of the murine fibroblast adapted strain, Kentucky A (KyA), of equine herpesvirus type 1 (EHV-1) in young horses.
Veterinary microbiology    February 1, 1996   Volume 48, Issue 3-4 353-365 doi: 10.1016/0378-1135(09)59999-3
Matsumura T, O'Callaghan DJ, Kondo T, Kamada M.The virulence of the cell culture adapted KyA strain of equine herpesvirus type 1 (EHV-1), which lacks at least six genes by deletions in its genome, was assessed by intranasal inoculation of six young horses that were serologically negative for EHV-1. No horses showed clinical signs, and a neutralizing antibody response against EHV-1 was detected in two horses which had antibodies against EHV-4 prior to the inoculation. A challenge experiment using a highly virulent strain of EHV-1 conducted 4 weeks later against 4 of the 6 horses inoculated intranasally with the KyA strain and 2 control hors...
Expression cloning and antigenic analysis of the nucleocapsid protein of equine arteritis virus.
Virus research    December 1, 1995   Volume 39, Issue 2-3 277-288 doi: 10.1016/0168-1702(95)00098-4
Chirnside ED, Francis PM, Mumford JA.A series of recombinant fusion proteins derived from equine arteritis virus (EAV) open reading frame (ORF) 7 have been used to define the immunoreactive region of the viral nucleocapsid (N) protein. Reactivities of recombinant N fusion proteins with post-infection equine sera in immunoblots and ELISAs indicate that the major nucleocapsid protein epitope is located within amino acid residues 1-69. In ELISAs two recombinant nucleocapsid fusion proteins containing residues 1-69 (rN1-69) and 1-28 (rN1-28) discriminated between pre- and post-infection, and pre- and post-vaccination serum samples. A...
The use of African horse sickness virus NS3 protein, expressed in bacteria, as a marker to differentiate infected from vaccinated horses.
Virus research    October 1, 1995   Volume 38, Issue 2-3 205-218 doi: 10.1016/0168-1702(95)00061-t
Laviada MD, Roy P, Sánchez-Vizcaíno JM, Casal JI.Segment 10 of the double-stranded RNA (dsRNA) genome from African horse sickness virus serotype 4 (AHSV-4) was cloned and sequenced. The sequence of the coding region showed a total length of 667 bp. Nucleotide comparisons showed a 95% sequence similarity between serotypes 4 and 9, and 76% between serotypes 4 and 3. cDNA clones containing the coding region were cloned in the vector pET3xb and expressed in Escherichia coli. The NS3 gene product was synthesised at very high level as an insoluble fusion protein. The recombinant protein was used in a differential ELISA to distinguish horses that w...
An assessment of mucosal immunisation in protection against Streptococcus equi (‘Strangles’) infections in horses.
Veterinary immunology and immunopathology    September 1, 1995   Volume 48, Issue 1-2 139-154 doi: 10.1016/0165-2427(95)05426-7
Wallace FJ, Emery JD, Cripps AW, Husband AJ.The ability of mucosally administered antigen to provide protection against Streptococcus equi ('Strangles') infections in horses was examined. First, an enzyme linked immunosorbent assay (ELISA) was developed to detect the immune status of horses to S. equi. This assay was used to select Strangles-naive horses for the study and also to monitor their response to immunisation. Potential vaccine candidates were: (a) orally administered paraformaldehyde killed S. equi; (b) intraperitoneally (IP) administered paraformaldehyde killed S. equi in a non-inflammatory adjuvant; (c) orally administered l...
Characteristics of equine herpesvirus 1 glycoproteins expressed in insect cells.
Veterinary microbiology    September 1, 1995   Volume 46, Issue 1-3 193-201 doi: 10.1016/0378-1135(95)00083-m
Whalley JM, Love DN, Tewari D, Field HJ.A series of recombinant baculoviruses containing genes for glycoproteins C, D, H and L of equine herpesvirus 1 (EHV-1) have been constructed, and the EHV-1 products characterised by gel electrophoresis and immunoblotting. The EHV-1 glycoproteins expressed in insect cells were similar but not identical in apparent sizes to those expressed in EHV-1 infected mammalian cells. Each of the EHV-1 products was recognised by convalescent equine sera, indicating that they were all targets for an equine immune response. Mice immunised with baculovirus-expressed EHV-1 gD and gC acquired an enhanced abilit...
Equine arteritis virus-neutralizing antibody in the horse is induced by a determinant on the large envelope glycoprotein GL.
The Journal of general virology    August 1, 1995   Volume 76 ( Pt 8) 1989-1998 doi: 10.1099/0022-1317-76-8-1989
Chirnside ED, de Vries AA, Mumford JA, Rottier PJ.Complementary DNAs encoding ORFs 2 to 7 equine arteritis virus (EAV) have been cloned into the expression vector pGEX to produce glutathione-S-transferase fusion proteins. Recombinant proteins were affinity purified and screened in ELISA with equine sera to identify immunoreactive polypeptides. The large envelope glycoprotein (GL) was identified as the most reactive to EAV-positive equine sera and an immuno-dominant epitope was mapped between amino acids 55 and 98 by subcloning and expression. A fusion protein covering this region and a GL-specific synthetic peptide (residues 75 through 97) in...
Detection of tetanus toxoid-specific memory T cells in equine lymph nodes but not in peripheral blood.
Research in veterinary science    July 1, 1995   Volume 59, Issue 1 79-81 doi: 10.1016/0034-5288(95)90035-7
Frayne J, Stokes CR.The use of tetanus toxoid as a recall antigen to investigate equine immune responses would be, in theory, a useful and cost-effective model in vitro. However, by using various regimens for culturing peripheral blood mononuclear cells from horses previously immunised with toxoid no proliferative response to the antigen was obtained in vitro, whereas lymph node mononuclear cells from the same animals proliferated significantly in response to it. The lack of response by the peripheral blood mononuclear cells was not due to the presence of a suppressive factor but to a lack of recognition of the a...
Development and evaluation of an ELISA using recombinant fusion protein to detect the presence of host antibody to equine arteritis virus.
Journal of virological methods    July 1, 1995   Volume 54, Issue 1 1-13 doi: 10.1016/0166-0934(95)00020-u
Chirnside ED, Francis PM, de Vries AA, Sinclair R, Mumford JA.A recombinant glutathione-S-transferase fusion protein expressing amino acids 55-98 of equine arteritis virus (EAV) GL (rGL 55-98) was tested in an ELISA for its ability to detect serum antibodies to EAV. Host antibodies induced following EAV infection bound the recombinant antigen by ELISA. The ELISA specificity and sensitivity were determined with a panel of equine sera including postinfection and postvaccination samples. A good correlation existed between EAV neutralizing antibody titers and ELISA absorbance values (r = 0.827). The sensitivity and specificity of the ELISA were 99.6 and 90.1...
Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses.
Vaccine    February 1, 1995   Volume 13, Issue 3 281-288 doi: 10.1016/0264-410x(95)93315-z
Hunt AR, Roehrig JT.In order to define more precisely the protective epitope encoded within the first 25 amino acids (aa) of the E2 glycoprotein of the Trinidad donkey strain of Venezuelan equine encephalomyelitis (VEE) virus, we examined the immunogenicity of smaller peptides within the first 19 aa. pep1-9 and pep3-10 elicited virus-reactive antibody, but failed to protect mice from virus challenge. Additionally, pep3-10 was identified by a competitive binding assay using overlapping peptide octamers as the putative binding site of the antipeptide monoclonal antibody (mAb) 1A2B-10. Since the E2 amino-terminal se...
Detection of equine arteritis virus (EAV) by polymerase chain reaction (PCR) and differentiation of EAV strains by restriction enzyme analysis of PCR products.
Archives of virology    January 1, 1995   Volume 140, Issue 8 1483-1491 doi: 10.1007/BF01322675
Sekiguchi K, Sugita S, Fukunaga Y, Kondo T, Wada R, Kamada M, Yamaguchi S.A polymerase chain reaction (PCR) based assay capable of detecting and differentiating seven strains of equine arteritis virus (EAV) from around the world was developed. The primers for the PCR were chosen from the ORF6 gene encoding the unglycosylated membrane protein (M). Viral RNA from cell culture fluids infected with each of the seven EAV strains and RNA from the live vaccine, Arvac, was detected by PCR using four sets of primers. The sensitivity of detection was increased from 100 to 1,000 times by performing nested PCR enabling the detection of RNA at a level of 0.5-5 PFU. Differentiati...
Distribution of equid herpesvirus-1 (EHV-1) in the respiratory tract of ponies: implications for vaccination strategies.
Equine veterinary journal    November 1, 1994   Volume 26, Issue 6 466-469 doi: 10.1111/j.2042-3306.1994.tb04051.x
Kydd JH, Smith KC, Hannant D, Livesay GJ, Mumford JA.Twelve adult ponies and 2 conventional foals were exposed to 10(6.6) TCID50 of Equid herpesvirus-1 (EHV-1), strain Ab4 and samples of respiratory tract tissues were recovered. Infectious virus in tissue homogenates was detected using susceptible cell monolayers and expression of viral antigens was monitored using indirect immunoperoxidase histochemistry of paraffin sections. The results illustrated the rapid dissemination of EHV-1 throughout the respiratory tract, with early replication in the lungs one day after exposure. Endothelial cell infection was prominent in all areas of the nasopharyn...
African horsesickness: pathogenesis and immunity.
Comparative immunology, microbiology and infectious diseases    August 1, 1994   Volume 17, Issue 3-4 275-285 doi: 10.1016/0147-9571(94)90047-7
Burrage TG, Laegreid WW.African horsesickness (AHS) is a serious, non-contagious disease of horses and other solipeds caused by an arthropod-borne orbivirus of the family Reoviridae. In horses, AHS causes three distinct clinicopathologic syndromes, the pulmonary, cardiac and fever forms of the disease. Recent work has shown that the primary determinant of the form of disease expressed by naive horses is the virulence of the virus inoculum. Horses which recover from AHS exhibit solid humoral immunity against homologous challenge. Protective antibodies appear to be directed towards neutralizing epitopes on AHS virus VP...
Expression of functional protease and subviral particles by vaccinia virus containing equine infectious anaemia virus gag and 5′ pol genes.
The Journal of general virology    April 1, 1994   Volume 75 ( Pt 4) 895-900 doi: 10.1099/0022-1317-75-4-895
McGuire TC, O'Rourke KI, Baszler TV, Leib SR, Brassfield AL, Davis WC.Cells infected with vaccinia viruses expressing the equine infectious anaemia virus (EIAV) gag gene (VGag) or gag plus the 5' pol encoding protease (VGag/PR) were evaluated with monoclonal antibody to a p26 capsid protein linear epitope (QEISKFLTD). Both recombinant viruses expressed Gag precursor protein (55K) whereas only VGag/PR expressed a detectable Gag-Pol fusion protein (82K) with a functional protease, shown by subviral particles containing processed p26. Horses inoculated with VGag/PR produced antibodies reactive with EIAV Gag proteins.
Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant.
Epidemiology and infection    April 1, 1994   Volume 112, Issue 2 421-437 doi: 10.1017/s0950268800057848
Mumford JA, Wilson H, Hannant D, Jessett DM.Equine influenza vaccines containing inactivated whole virus and Carbomer adjuvant stimulated higher levels and longer lasting antibody to haemagglutinin in ponies than vaccines of equivalent antigenic content containing aluminium phosphate adjuvants. Five months after the third dose of vaccine containing Carbomer adjuvant, ponies were protected against clinical disease induced by an aerosol of virulent influenza virus (A/equine/Newmarket/79, H3N8). In contrast ponies which received vaccine containing aluminium phosphate adjuvant were susceptible to infection and disease. There was an inverse ...
1 25 26 27 28 29 35